• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

James A. DeCaprio, M.D.

Associate Professor, Department of Medicine, Harvard Medical School

Discovery Leader, Center for Applied Cancer Sciences, Dana-Farber Cancer Institute

Active Staff and Clinical Associate in Medicine, Medical Oncology, Dana-Farber Cancer Institute

Senior Director, DF/HCC Monoclonal Antibody Core, Dana-Farber Cancer Institute

Associate Professor of Medicine, Medical Oncology, Dana-Farber Cancer Institute

Active Staff and Associate Physician, Medicine, Brigham And Women's Hospital

Contact Info

James DeCaprio
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Mailstop: Mayer 457
Phone: 617-632-3825
Fax: 617-582-8601
james_decaprio@dfci.harvard.edu

Assistant

Tracy Baker
Medical Oncology
Dana-Farber Cancer Institute
Mailstop: DFCI MA440
Phone: 617-582-8605
Fax: 617-582-8601
tracy_baker@dfci.harvard.edu

DF/HCC Program Affiliation

Cancer Cell Biology
Cancer Genetics

DF/HCC Associations

Director, Monoclonal Antibody
Member, Center Scientific Council

Research Abstract

This laboratory is focused on understanding the mechanisms of cellular transformation. In particular, we study how SV40 large T antigen (T Ag) is capable of inducing all of the cellular changes associated with oncogenic transformation. Cellular transformation by T Ag is dependent, at least in part, on inactivation of cellular tumor suppressers. Genetic analysis has led to identification of three transforming domains of T Ag: a C-terminal domain that binds the p53 tumor suppresser and the p300/CBP transcription coactivators; the LxCxE domain that binds the retinoblastoma (pRB) family of tumor suppressers, including pRB, p107 and p130 and an N-terminal domain that resembles the J domain found in the DnaJ/hsp40 family of molecular chaperones. The laboratory seeks to identify novel cellular targets of SV40 T Ag. We have identified a novel E3 ubiquitin ligase, CUL7/FBXW8, that binds to T Ag and appears to contribute to viral oncogenesis.

Publications

  • Skaar JR, Florens L, Tsutsumi T, Arai T, Tron A, Swanson SK, Washburn MP, DeCaprio JA.PARC and CUL7 form atypical cullin RING ligase complexes.Cancer Res 2007 Mar 1;67(5):2006-14.
    17332328
  • Poulin DL, DeCaprio JA.Is there a role for SV40 in human cancer?.J Clin Oncol 2006 Sep 10;24(26):4356-65.
    16963733
  • Kasper JS, Arai T, Decaprio JA.A novel p53-binding domain in CUL7.Biochem Biophys Res Commun 2006 Jul 13.
    16875676
  • Poulin DL, DeCaprio JA.The carboxyl-terminal domain of large T antigen rescues SV40 host range activity in trans independent of acetylation.Virology 2006 May 25;349(1):212-21.
    16510165
  • Kasper JS, Kuwabara H, Arai T, Ali SH, DeCaprio JA.Simian virus 40 large T antigen's association with the CUL7 SCF complex contributes to cellular transformation.J Virol 2005 Sep;79(18):11685-92.
    16140746
  • Skaar JR, Arai T, DeCaprio JA.Dimerization of CUL7 and PARC is not required for all CUL7 functions and mouse development.Mol Cell Biol 2005 Jul;25(13):5579-89.
    15964813
  • Litovchick L, Chestukhin A, DeCaprio JA.Glycogen synthase kinase 3 phosphorylates RBL2/p130 during quiescence.Mol Cell Biol 2004 Oct;24(20):8970-80.
    15456871
  • Buchmann AM, Skaar JR, DeCaprio JA.Activation of a DNA damage checkpoint response in a TAF1-defective cell line.Mol Cell Biol 2004 Jun;24(12):5332-9.
    15169897
  • Arai T, Kasper JS, Skaar JR, Ali SH, Takahashi C, DeCaprio JA.Targeted disruption of p185/Cul7 gene results in abnormal vascular morphogenesis.Proc Natl Acad Sci U S A 2003 Aug 19;100(17):9855-60.
    12904573